SCHEMBL3679332

SCHEMBL3679332

CCC(C(=O)N1CCN(c2ccc(C(=O)NC(C)CC(C)C)cn2)CC1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 2/20 0.47
ALDH1A1 P00352 6/20 0.45
LMNA P02545 3/20 0.45
TSHR P16473 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
SCD O00767 1/20 0.45
MAPK1 P28482 1/20 0.45
RECQL P46063 1/20 0.45
GAA P10253 1/20 0.45
HDAC1 Q13547 5/20 0.45
HDAC3 O15379 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 3/20 0.42
HSD17B10 Q99714 2/20 0.42
ADRB2 P07550 1/20 0.42
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666195 0.91 RAB9A (0.49) P2RY12ALDH1A1LMNATSHRNPSR1
SCHEMBL3677187 0.88 LMNA (0.55) ALDH1A1LMNATSHRNPSR1SCD
SCHEMBL3669499 0.87 SCD (0.44) P2RY12ALDH1A1LMNANPSR1SCD
SCHEMBL3670314 0.85 SCD (0.63) P2RY12ALDH1A1LMNATSHRNPSR1
SCHEMBL3674061 0.84 SCD (0.48) P2RY12ALDH1A1LMNATSHRNPSR1
SCHEMBL3669122 0.82 ALDH1A1 (0.51) P2RY12ALDH1A1LMNATSHRNPSR1
SCHEMBL14181741 0.82 GAA (0.52) P2RY12ALDH1A1LMNATSHRNPSR1
SCHEMBL3673395 0.82 SCD (0.43) P2RY12ALDH1A1SCDHDAC1HDAC6
SCHEMBL3675159 0.81 ALDH1A1 (0.50) P2RY12ALDH1A1LMNATSHRNPSR1
SCHEMBL3677314 0.81 RAB9A (0.65) ALDH1A1LMNATSHRNPSR1SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP claimed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US claimed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US claimed
EP-1763350-B1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2011-12-21 EP disclosed
EP-2266566-A2 Nicotinamide derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. (CA) 2010-12-29 EP disclosed
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2009-08-06 US disclosed
US-20070087363-A1 Therapeutic methods, compounds and compositions MYRIAD GENETICS, INCORPORATED (US) 2007-04-19 US disclosed
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119251-A1 Nicotinamide derivatives and their use as therapeutic agents NAMPT, NNT, NNMT P2RY12 1164/4885ALDH1A1 1127/4885LMNA 175/4885
US-20070087363-A1 Therapeutic methods, compounds and compositions APP, BACE1, PSEN1 P2RY12 2489/4885ALDH1A1 3898/4885LMNA 369/4885
US-20090197894-A1 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS NAMPT, NNT, NNMT P2RY12 1164/4885ALDH1A1 1127/4885LMNA 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.